Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Research output: Contribution to journalArticle

Bibtex

@article{6fa86209d80644cebce06277f43f3b19,
title = "Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.",
abstract = "The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).",
author = "Emma Gustb{\'e}e and Helga Tryggvadottir and Andrea Markkula and Maria Simonsson and Bj{\"o}rn Nodin and Karin Jirstr{\"o}m and Carsten Rose and Christian Ingvar and Signe Borgquist and Helena Jernstr{\"o}m",
year = "2015",
doi = "10.1186/s12907-015-0008-2",
language = "English",
volume = "15",
journal = "BMC Clinical Pathology",
issn = "1472-6890",
publisher = "BioMed Central",

}